Emerson brings a broad range of expertise in equitable health access to the clinical trial super network
WASHINGTON, DC, September 29, 2023 /24-7PressRelease/ — hyperCORE International is pleased to welcome Emerson Clinical Research Institute to its collaborative super network of clinical trial sites. This new addition to its family of alliance partners allows the organization to continue expanding its reach and capabilities across the clinical research arena.
The Emerson Clinical Research Institute (ECRI), its Emerson Community Clinic (ECC) and Emerson Diversity Health Foundation (EDHF) have worked together to advance equitable health access, understanding, and outcomes for diverse racial and ethnic Hispanic populations and other disadvantaged communities. The integrated work of the three entities provides health testing, education and resources, low-cost patient healthcare, as well as education about and access to participation in clinical research studies.
Founded by CEO and President, Dr. Fabian Sandoval, Emerson Clinical Research Institute’s research team has evaluated, screened, and/or educated over 68,000 racially and ethnically diverse people and enrolled over 3,400 primarily Hispanic patients in over 300 clinical trials. Emerson’s study/ patient population is approximately 80% Hispanic, 15% African American, 4% white, and 1% other. Most Emerson staff members are bi-lingual, all demonstrate cultural effectiveness and sensitivity, and clinic locations provide access to transportation for clinical trial participants who need it.
On the decision to join hyperCORE, Dr. Sandoval expressed, “There is power in numbers by joining forces. By working with members of hyperCORE, I hope to gain insight into improved budget and contract negotiations, as well as the sustainable study pipeline. Knowing that members of hyperCORE have similar visions for success, in creating standardized systems across departments along with a strong reputation, ensures that we will all provide sponsors with the best quality possible for reliable study data and results.”
Dr. Sandoval’s diversified research career has been in academia, healthcare systems and the public sector over the past 25 years. His research encompasses pioneering work at the National Institutes of Neurological Disorders and Stroke (NINDS), focusing on early-onset Alzheimer’s Disease, Creutzfeldt-Jakob Disease, and epilepsy in post-traumatic brain injury patients. He served as the Supervisory Research Integrity & Compliance Officer in the Army Human Research Protections Office in the Office of the Army Surgeon General. Notably, Dr. Sandoval won four Emmys for his TV show “Tu Salud Tu Familia” (Your Family Your Health) and is a regular medical contributor to Telemundo News. He is also a prominent figure in community engagement, advocating for minority participation in clinical trials and healthcare access through initiatives like the Emerson Community Clinic and Emerson Diversity Health Foundation.
“I’ve had the pleasure working with Dr. Fabian Sandoval on the Diversity Committee with SCRS and appreciate his passion and work mission in enrollment and inclusion of diverse study participants,” shared Karri Venn, CEO of hyperCORE and COO at Centricity Research. “One of hyperCORE International’s pillars is Diversity/Equity and Inclusion and thus having his team was an easy decision. We very much look forward to his insights to further our best practices for our industry partners.”
A collaborative super network of clinical trial companies, hyperCORE International is comprised of over 100 clinical trial sites across North and South America and offers streamlined efficiencies such as centralized budget and contracts, and shared platforms for rapid scalability. The network also offers unparalleled access to diverse populations and a depth of expertise across vaccines, metabolic disorders, dermatology, and many additional therapeutic areas.
Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 100 active research sites on two continents and five countries. Each of its alliance partners have decades of clinical research experience and have collectively completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 randomized patients. Each partner operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.
hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.
For the original version of this press release, please visit 24-7PressRelease.com here